Drug Profile


Alternative Names: Baclofen/sorbitol/naltrexone; Naltrexone/baclofen/sorbitol; Naltrexone/sorbitol/baclofen; Pleocompound PXT3003; PXT-03003; PXT-3003; Sorbitol/baclofen/naltrexone; Sorbitol/naltrexone/baclofen

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Pharnext
  • Class Aminobutyric acids; Analgesics; Antispastics; Cyclopropanes; Morphinans; Muscle relaxants; Small molecules; Sugar alcohols
  • Mechanism of Action GABA B receptor agonists; Opioid receptor antagonists; PMP22 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Charcot-Marie-Tooth disease
  • New Molecular Entity No

Highest Development Phases

  • Phase III Charcot-Marie-Tooth disease

Most Recent Events

  • 13 Jan 2017 Pharnext, SynteractHCR and INC Research plan the extension phase III PLEO-CMT-FU trial for Charcot-Marie-Tooth disease (In adolescents, In adults) in USA, Belgium, France, Canada, Germany, Spain, Netherlands and United Kingdom (PO, Liquid) (NCT03023826)
  • 20 Dec 2016 Pharnext completes enrolment in the phase II PLEO CMT trial in Charcot-Marie-Tooth disease in USA, Belgium, Canada, France, Germany, Netherlands, Spain and United Kingdom
  • 17 Nov 2016 An independent Data Safety Monitoring Board recommends continuation of the phase III PLEO-CMT trial in Charcot-Marie-Tooth disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top